CoChat

Aptamer-conjugated nanomaterials for specific cancer cell recognition and targeted cancer therapy

Open access
Liu, Qiaoling, Jin, Chen, Wang, Yanyue, Fang, Xiaohong, Zhang, Xiaobing, Chen, Zhuo, Tan, Weihong · 2014 · NPG Asia Materials
Cited by 141

The DOI matches its Crossref record.

Abstract

Based on their unique advantages, increasing interest has been shown in the use of aptamers as target ligands for specific cancer cell recognition and targeted cancer therapy. Recently, the development of aptamer-conjugated nanomaterials has offered new therapeutic opportunities for cancer treatment with better efficacy and lower toxicity. We highlight some of the promising classes of aptamer-conjugated nanomaterials for the specific recognition of cancer cells and targeted cancer therapy. Recent developments in the use of novel strategies that enable sensitive and selective cancer cell recognition are introduced. In addition to targeted drug delivery for chemotherapy, we also review how aptamer-conjugated nanomaterials are being incorporated into emerging technologies with significant improvement in efficiency and selectivity in cancer treatment. New methods of integrating aptamers with various types of nanomaterials are summarized, highlighting promising classes of aptamer-conjugated nanoparticles for efficient cancer cell recognition and the targeted delivery of drugs. In addition, emerging technologies for cancer treatment using nanomaterials as therapeutic drugs are discussed. These aptamer-conjugated nanomaterials will benefit cancer treatment through increased specificity and efficacy as well as reduced toxicity. A major challenge in cancer therapy is the selective targeting of cancerous cells to enhance treatment efficiency and reduce the side effects for patients. A variety of nanostructured materials have recently been developed that, when combined with ligands, are able to recognize the target cells through antigens or receptors. Qiaoling Liu from Hunan University and colleagues in China and the United States review the use of DNA aptamers as ligands. These short, synthetic oligonucleotide strands are cost-effective, exhibit low toxicity and can be attached to a range of nanomaterials - from liposomes and hydrogels to inorganic nanoparticles - to endow them with sensitive and selective cell-recognition abilities. Furthermore, the resulting hybrid nanomaterials can be used in conjunction with conventional treatments, such as photodynamic and photothermal therapies. Although hurdles in their toxicity and efficiency remain to be overcome before they are suitable for real-life cancer treatments, aptamer-conjugated nanomaterials have emerged as a promising theranostic platform.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/am.2014.12

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 141

Metadata

Authors
Liu, Q., Jin, C., Wang, Y., Fang, X., Zhang, X., Chen, Z., & Tan, W.
Venue
NPG Asia Materials
Published
2014-04
Volume
6
Issue
4
Pages
e95-e95
ISSN
  • 1884-4049 (ISSN-L)
  • 1884-4057
OpenAlex
W2016419370
Cited by
141
References
0
FWCI
5.01
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aptamer-conjugated nanomaterials for specific cancer cell recognition and targeted cancer therapy. https://app.cochat.ai/papers/10.1038/am.2014.12
The paper
Liu, Q., Jin, C., Wang, Y., Fang, X., Zhang, X., Chen, Z., & Tan, W. (2014). Aptamer-conjugated nanomaterials for specific cancer cell recognition and targeted cancer therapy. NPG Asia Materials. https://doi.org/10.1038/am.2014.12

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.